Treatment with BRAF inhibitors is often accompanied by paradoxical MAP kinase reactivation that limits the clinical response.350 The combination with MEK inhibitors alleviates this situation to some extent, thereby significantly improving the response rate and survival of patients with melanoma. The gene discussed is BRAF; the disease is melanoma.